Challenges in developing new antibacterial drugs

Current Opinion in Investigational Drugs

Volumn 10, Issue 2, 2009, Pages 157-163

  Williams, K J ^a   Bax, R P ^b  

^a KW Drug Developments   (United Kingdom)

^b Chatsworth House   (United Kingdom)

Author keywords

Antibacterial discovery; Drug development; Gram negative; Guidelines; Resistance

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; GENERIC DRUG; LINEZOLID; POSIZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BIOTECHNOLOGY; DRUG INDUSTRY; DRUG SCREENING; DRUG SYNTHESIS; DRUG USE; GENOMICS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MEDICAL RESEARCH; PRACTICE GUIDELINE; REVIEW;

ANTI-BACTERIAL AGENTS; BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GUIDELINES AS TOPIC; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 62249124839     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Finch R: Innovation - drugs and diagnostics. J Antimicrob Chemother (2007) 60(Suppl 1):i79-i82. •• An EU perspective and details on the lack of new antibacterials.
2. Cassell GH: ASM Task Force urges broad program on antimicrobial resistance. ASM News (1995) 61:116-120.
3. Bad bugs, no drugs: As antibiotic discovery stagnates a public health crisis brews: Infectious Diseases Society of America, Arlington, VA, USA (2004). http://www.idsociety.org/badbugsnodrugs.html •• The initial IDSA paper discussing the lack of new antibacterial drugs. Since then there have been Congress hearings, but the industry awaits some encouragement.
4. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG, Antimicrobial Availability Task Force of the Infectious Diseases Society of America: Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis (2006) 42(5):657-668.
5. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr, Infectious Diseases Society of America: The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis (2008) 46(2):155-164. •• A key update on antibacterial drugs from the IDSA.
6. Huttunen J, Davey P: The Copenhagen recommendations. Report from the invitational EU conference on the microbial threat. Copenhagen, Denmark (1998):September 9-10. http://www.im.dk/publikationer/micro98/recommen.htm
7. Norrby SR, Nord CE, Finch R, European Society of Clinical Microbiology and Infectious Diseases: Lack of development of new antimicrobial drugs: A potential serious threat to public health. Lancet Infect Dis (2005) 5(2):115-119. •• This paper discusses the concerns of antibacterial resistance in Europe.
8. World health report on infectious diseases, 2000. Overcoming antimicrobial resistance. WHO, Geneva, Switzerland (2000). http://www.who.int/infectious-disease-report/2000/other-versions/ index-rpt2000-text.html
9. Charles PGP, Grayson ML: The dearth of new antibiotic development: Why we should be worried and what we can do about it. Med J Aust (2004) 181(10):549-553. • An excellent summary on the lack of new antibiotic development and what can be done to address it.
10. Shlaes DM, Moellering RC Jr: The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis (2002) 34(3):420-422. • An industry perspective on the lack of new antibacterials.
11. Tillotson GS: Antibiotic development: A victim of market forces? IDrugs (2008) 11(5):340-346. • An industry insight on antibiotic development.
12. Overbye KM, Barrett JF: Antibiotics: Where did we go wrong? Drug Discov Today (2005) 10(1):45-52.
13. Smith C, Burley C, Ireson M, Johnson T, Jordan D, Knight S, Mason T, Massey D, Moss J, Williams K: Clinical trials of antimicrobial agents: A practical guide to design and analysis. Statisticians in the Pharmaceutical Industry Working Party. J Antimicrob Chemother (1998) 41(4):467-480.
14. Bax RP: Antibiotic resistance: A view from the pharmaceutical industry. Clin Infect Dis (1997) 24(Suppl 1):S151-S153. • The development of cefuroxime, cefuroxime axetil, cefotaxime, ceftazidime, moxalactam, cefotetan, meropenem, daptomycin, AZD-2563 and other drugs that reached the market is presented.
15. Slama TG: Gram-negative antibiotic resistance: There is a price to pay. Crit Care (2008) 12(Suppl 4):S4.
16. Harrison PF, Lederberg J (Eds): Antimicrobial Drug Resistance: Issues and Options. Workshop report. National Academy Press, Washington, DC, USA (1998).
17. Shlaes DM: The abandonment of antibacterials: Why and wherefore? Curr Opin Pharmacol (2003) 3(5):470-473.
18. Clarke T: Drug companies snub antibiotics as pipeline threatens to run dry. Nature (2003) 425(6955):225.
19. Nathan C: Antibiotics at the crossroads. Nature (2004) 431(7011):899-902.
20. Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H: Antibacterial research and development in the 21st century - An industry perspective of the challenges. Curr Opin Microbiol (2004) 7(5):445-450.
21. Stein J: Innovative antibacterial drugs: Nothing ventured, nothing gained. Expert Opin Investig Drugs (2005) 14(2):107-109.
22. Barrett JF: Can biotech deliver new antibiotics? Curr Opin Microbiol (2005) 8(5):498-503.
23. Dickson M, Gagnon JP: Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov (2004) 3(5):417-429.
24. Finch RG: Introduction: Standards of antibacterial performance. Clin Microbiol Infect (2004) 10(Suppl 2):1-5.
25. Mackay M, Street SD, McCall JM: Risk reduction in drug discovery and development. Curr Top Med Chem (2005) 5(11):1087-1090.
26. Gustafsson I, Cars O: The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae. Clin Microbiol Infect (2004) 10(10):934-937.
27. Carpenter CF, Chambers HF: Daptomycin: Another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis (2004) 38(7):994-1000.
28. Hutchinson DK: Oxazolidinone antibacterial agents: A critical review. Curr Top Med Chem (2003) 3(9):1021-1042.
29. Luzhetskyy L, Pelzer S, Bechtold A: The future of natural products as a source of new antibiotics. Curr Opin Investig Drugs (2007) 8(8):808-813.
30. Dougherty TJ, Barrett JF, Pucci MJ: Microbial genomics and novel antibiotic discovery: New technology to search for new drugs. Curr Pharm Des (2002) 8(13):1119-1135.
31. Holzman TF, Hebert EJ: Transforming the work of early-stage drug discovery through bioprocess informatics. Drug Disc Today (2005) 10(1):61-67.
32. Payne DJ, Gwynn MN, Holmes DJ, Rosenberg M: Genomic approaches to antibacterial discovery. Methods Mol Biol (2004) 266:231-259.
33. Betz UA, Farquhar R, Ziegelbauer K: Genomics: Success or failure to deliver drug targets? Curr Opin Chem Biol (2005) 9(4):387-391.
34. Rachakonda S, Cartee L: Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics. Curr Med Chem (2004) 11(6):775-793.
35. Bush K: Antibacterial drug discovery in the 21st century. Clin Microbiol Infect (2004) 10(Suppl 4):10-17.
36. Showalter HDH: Outwitting nature: Future trends for antimicrobial therapy. Tom D Rowe 55th Annual Pharmacy Lectures, University of Michigan, Ann Arbor, MI, USA (2006). http://sitemaker.umich.edu/cop. continuing.ed/files/showalter- additional-handout-materials.pdf • A good summary of recently developed antibacterials.
37. Chopra I, Hesse L, O'Neill AJ: Exploiting current understanding of antibiotic action for discovery of new drugs. J Appl Microbiol (2002) 92(Suppl):4S-15S.
38. Dougherty TJ, Barrett JF, Pucci MJ: Microbial genomics and novel antibiotic discovery: New technology to search for new drugs. Curr Pharm Des (2002) 8(13):1119-1135.
39. Isaacson RE: Genomics and the prospects for the discovery of new targets for antibacterial and antifungal agents. Curr Pharm Des (2002) 8(13):1091-1098.
40. Lieberman LB, Wootan MG: Protecting the crown jewels of medicine. Center for Science in the Public Interest (1998). http://www.cspinet. org/reports/abiotic.htm
41. Guidelines for the clinical evaluation of anti-infective drugs (adults and children): FDA, Rockville, MD, USA (1977). http://www.fda.gov/CDER/ GUIDANCE/old047fn.pdf
42. Finch RG: The clinical evaluation of antibacterial drugs: Guidelines of the British Society for Antimicrobial Chemotherapy. Eur J Clin Microbiol Infect Dis (1990) 9(7):542-547.
43. Beam TR Jr, Gilbert DN, Kunin CM: General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis (1992) 15(Suppl 1):S5-S32.
44. Beam TR Jr, Gilbert DN, Kunin CM: European guidelines for antiinfective drug products. Introduction. Clin Infect Dis (1993) 17(4):787-788.
45. Published guidance documents: FDA, Rockville, MD, USA (1998). http://www.fda.gov/cvm/Guidance/published.htm
46. Legal requirements for systemic antibacterial drug products intended for human use: FDA, Rockville, MD, USA (2003). http://www.fda.gov/OHRMS/ DOCKETS/98fr/00n-1463-nfr00001.pdf
47. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJC, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis (2005) 41(10):1373-1406.
48. EFPIA response to European Commission consultation on 'Health in Europe: A strategic approach': EFPIA, Belgium, Brussels (2007). http://212.3.246.100/Objects/2/Files/healthineurope2007.pdf
49. Hartman CS, Leach TS, Kaja RW, Schaser RJ, Todd WM, Hafkin B: Linezolid in the treatment of vancomycin-resistant Enterococcus: A dose comparative, multicenter phase III trial. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf (2000) 40:488.
50. The rise of antibiotic-resistant infections: FDA, Rockville, MD, USA (1995). http://www.fda.gov/fdac/features/795-antibio.html
51. Mandell L, Tillotson G: Safety of fluoroquinolones: An update. Can J Infect Dis (2002) 13(1):54-61.
52. Clay D, Hanson JS, Pope SD, Rissmiller RW, Purdum PP III, Banks PM: Brief communication: Severe hepatotoxicity of telithromycin: Three case reports and literature review. Annals Internal Med (2006) 144:415-420.
53. B eekmann SK, Gilbert DN, Polgreen PM; The IDSA Emerging Infections Network: Toxicity of extended courses of linezolid: Results of an Infectious Diseases Society of America emerging infection network survey. Diagnostic Micro Inf Dis (2008) 62:407-410.
54. A public health action plan to combat antimicrobial resistance: Centers for Disease Control and Prevention, Atlanta, GA, USA (2008). http://www.cdc.gov/drugresistance/actionplan/aractionplan.pdf
55. Powers JH: Development of drugs for antimicrobial-resistant pathogens. Curr Opin Infect Dis (2003) 16(6):547-551.
56. Expanded access and expedited approval of new therapies related to HIV/AIDS: FDA, Rockville, MD, USA (2008). http://www.fda.gov/oashi/aids/ expanded.html
57. Bjerrum OJ: New safe medicines faster: A proposal for a key action within the European Union's 6th framework programme. Pharmacol Toxicol (2000) 86(Suppl 1):23-26.
58. Stein RL: A new model for drug discovery - meeting our societal obligation. Drug Discov Today (2003) 8(6):245-248.